

METech
METECH INTERNATIONAL LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration Number 199206445M)

MONTHLY UPDATE FOR FEBRUARY 2025

The board of directors (the “**Board**”) of Metech International Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) would like to provide an update on the following:

1) The appointment of executive officers, including, but not limited to, the Chief Financial Officer (or a person with equivalent authority) of the Company

The Company is still in the midst of exploring the appointment of a potential candidate for the role of Chief Financial Officer, and will submit the necessary documents to its continuing sponsor for their assessment and due diligence in due course.

The Company will make the necessary announcement(s) on SGXNet should the appointment of the Chief Financial Officer materialise in due course.

2) The Company’s operations

(a) Lab-grown diamond business

For the current lab-grown diamond business, the Company is exploring how it can be transformed into new uses in emerging high-tech applications, which may gradually open new market opportunities and drive further growth for the industry. In this regard, the Company has been in active discussions with several enterprises located in Chengdu and the Sichuan Institute of the Chinese Academy of Sciences to promote the development of its lab-grown diamond business and in the application in emerging technologies. Additionally, the Company is actively engaging with other PRC-based research institutions to explore collaboration opportunities for the development of this new market segment using the Company’s existing machineries.

Given the increasingly complex market dynamics and ongoing global geopolitical tensions, the Company has been making a conscious effort to expand its market share within the lab-grown diamond industry in the PRC. However, given the challenging economic climate in the PRC, which has not met expectations, the Company is making the necessary adjustments to its business model, resulting in an impact on our sales across all aspects. Accordingly, the Company is currently still reviewing the lab-grown diamond business model, and will provide updates to shareholders on any material developments as they arise.

(b) The Joint Venture

To create sustainable business streams and enhance shareholders’ value, the Company had, on 25 June 2024, through its wholly-owned subsidiary, Asian Green Tech Pte Ltd, entered into a joint venture agreement with Colorful Paradise Agricultural Cooperation Co., Ltd. (多彩樂園農業合作 有限公司) (“**CPAC**”) to incorporate a joint venture company in Singapore (“**JV Company**”). Details of the joint venture and its business are set out in the Company’s announcement dated 25 June 2024. The Company envisages the JV Company to be incorporated by the end of the first quarter of the current financial year ending 31 December 2025 (“**FY2025**”).

The Company wishes to announce that the biomass carbon reduction system machines is in the midst of the final stages of testing and commissioning in Taiwan. For the avoidance of doubt, the expenses in relation to the tests for the machines have been solely borne by CPAC. Barring any unforeseen circumstances, the machines are expected to arrive by the end of the first quarter of FY2025. Concurrently, the Company has shortlisted two (2) locations for the machines to be stationed in Singapore as part of the trial phase (being a food court and a shopping centre). The Company expects to commence the Food Waste Business during the second quarter of FY2025. In this regard, the Company will be making the relevant announcements in accordance with the Catalyst Rules as and when there are material developments.

(c) The Health Supplements Business

The Company had diversified into the wholesale distribution of health supplements following the approval from shareholders at the extraordinary general meeting held on 30 December 2024 (the “**EGM**”).

As a matter of update to shareholders, following the fulfilment of the initial orders placed by JHBD Pte. Ltd. (“**JHBD**”), which has proven to be smooth sailing and economically beneficial, the Company had, on 27 February 2025, entered into a non-binding memorandum of understanding with JHBD (the “**MOU**”). Under the MOU, both JHBD and the Company have agreed to cooperate on the following:

- i) The Company will tap on its supply chain advantages to provide JHBD with more cost-effective products; to ensure continuity for JHBD's products, the Company will have the first right of refusal to purchase the relevant goods from JHBD's existing suppliers. In subsequent stages of sales channel expansion, the Company can utilize its supply chain advantage to choose other suppliers. The Company may directly or via its subsidiaries cooperate on future development;
- ii) The Company will use its market advantage to expand JHBD's market and sales channels in Southeast Asia and China, and will also assist JHBD in obtaining the corresponding sales credential in China, so as to rapidly expand the scale of sale;
- iii) JHBD will make use of its product advantages to develop more competitive products in the market; and
- iv) Both the Company and JHBD will capitalize on the strength of each party, so as to improve competitiveness,

(collectively, the “**Proposed Collaboration**”).

Information about JHBD

JHBD is incorporated in the Republic of Singapore and has its registered office at 76 Playfair Road, #06-06, Singapore 367996. JHBD is a developer of bioactive peptides and basic scientific research products of life sciences, a provider of high-standard raw materials and a promoter of high-quality products.

For the avoidance of doubt, JHBD is an existing customer of the Group. Notwithstanding, JHBD, the sole director of JHBD, Ms. Sun Lili, and the shareholders of JHBD are independent third parties of the Group and the directors of the Company.

Rationale for the Proposed Collaboration

The Proposed Collaboration is part of the corporate strategy of the Group to further develop and explore new business opportunities and sales channel for the Health Supplements Business. The Board is of the view that the Proposed Collaboration will open up new market

opportunities, increase revenue stream and improve the prospects of the Group, so as to enhance shareholders' value.

Financial effects

The MOU is not expected to have a material impact on the net tangible assets per share and the earnings per share of the Company for the current financial year ending 31 December 2025. In the event that there is material impact, the Company will make a separate announcement on its financial impact in due course.

Interests of directors and controlling shareholders

None of the directors or controlling shareholders of the Company and their respective associates has any interest, direct or indirect (other than through their respective shareholdings (if any) in the Company), in the Proposed Collaboration.

The Company will make further announcements upon the execution of a definitive agreement and/or when there are material developments in respect of the Proposed Collaboration.

Barring unforeseen circumstances, the Company remains confident in the outlook and prospects of the health supplement business.

(d) Metech Performance Share Plan

Pursuant to the adoption of the Metech Performance Share Plan following shareholders' approval at the EGM, and as stated in the circular to shareholders dated 13 December 2024, the Company will be making an application to the SGX-ST for the listing and quotation of new shares of the Company ("**Shares**") to be allotted and issued pursuant to the Metech Performance Share Plan.

An announcement will be made by the Company upon receipt of the listing and quotation notice from the SGX-ST. The new Shares to be allotted and issued pursuant to the Metech Performance Share Plan are conditional upon the grant of the listing and quotation notice by the SGX-ST and the conditions in the listing and quotation notice being fulfilled. Shareholders should note that the approval of SGX-ST for the listing and quotation of any new Shares issued pursuant to the Metech Performance Share Plan, if obtained, shall not be taken as an indication of the merits of the Metech Performance Share Plan.

By Order of the Board of Directors of
Metech International Limited

Pang Wei Hao
Executive Director and Chief Executive Officer

28 February 2025

*This announcement has been prepared by the Company and reviewed by the Company's sponsor, Novus Corporate Finance Pte. Ltd. (the "**Sponsor**"), in compliance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalyst.*

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Pong Chen Yih, Chief Operating Officer, at 7 Temasek Boulevard, #04-02 Suntec Tower 1, Singapore 038987, telephone (65) 6950 2188.